Trends in antimalarial drug use in Africa

American Journal of Tropical Medicine and Hygiene

Volumn 89, Issue 5, 2013, Pages 857-865

  Flegg, Jennifer A ^a   Metcalf, Charlotte J E ^a   Gharbi, Myriam ^b,c   Venkatesan, Meera ^d   Shewchuk, Tanya ^e   Sibley, Carol Hopkins ^f   Guerin, Philippe J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c EHESP Rennes ^*  (France)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e POPULATION SERVICES INTERNATIONAL   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMISININ; CHLOROQUINE; MOLECULAR MARKER; PYRIMETHAMINE PLUS SULFADOXINE;

AFRICA; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INFORMATION; DRUG USE; HEALTH CARE POLICY; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; METHODOLOGY; MULTICENTER STUDY; PLASMODIUM FALCIPARUM; PREVALENCE; REDUCTION; TREND STUDY;

AFRICA; ANTIMALARIALS; ARTEMISININS; CHLOROQUINE; DRUG COMBINATIONS; DRUG RESISTANCE; HEALTH SURVEYS; HUMANS; MALARIA, FALCIPARUM; MODELS, STATISTICAL; PLASMODIUM FALCIPARUM; PYRIMETHAMINE; SULFADOXINE; TIME FACTORS;

EID: 84888618505     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.13-0129     Document Type: Article

References (31)

1. Nuwaha F, 2001. The challenge of chloroquine-resistant malaria in sub-Saharan Africa. Health Policy Plan 16: 1-12.
2. Greenwood B, 2009. Can malaria be eliminated? Trans R Soc Trop Med Hyg 103S: S2-S5.
3. Roberts L, Enserink M, 2007. Did they really say⋯ eradication? Science 318: 1544-1545.
4. Harinasuta T, Suntharasamai P, Viravan C, 1965. Chloroquineresistant falciparum malaria in Thailand. Lancet 2: 657-660.
5. Moore DV, Lanier JE, 1961. Observations on two Plasmodium falciparum infections with an abnormal response to chloroquine. Am J Trop Med Hyg 10: 5-9.
6. Young MD, Moore DV, 1961. Chloroquine resistance in Plasmodium falciparum. Am J Trop Med Hyg 10: 317-320.
7. Kihamia CM, Gill HS, 1982. Chloroquine-resistant falciparum malaria in semi-immune African Tanzaniana. Lancet 2: 43.
8. Fogh S, Jepsen S, Effersoe P, 1979. Chloroquine-resistant Plasmodium falciparum malaria in Kenya. Trans R Soc Trop Med Hyg 73: 228-229.
9. Hellgren U, Ardal OK, Lebbad M, Rombo L, 1987. Is chloroquineresistant Plasmodium falciparum malaria emerging in Senegal or The Gambia? Trans R Soc Trop Med Hyg 81: 728.
10. Kyronseppa H, Lumio J, Ukkonen R, Pettersson T, 1984. Chloroquine-resistant malaria from Angola. Lancet 1: 1244.
11. Korenromp EL, Williams BG, Gouws E, Dye C, Snow RW, 2003. Measurement of trends in childhood malaria mortality in Africa: an assessment of progress toward targets based on verbal autopsy. Lancet Infect Dis 3: 349-358.
12. Trape JF, 2001. The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg 64 (Suppl): 12-17.
13. Bjorkman A, Phillips-Howard P, 1990. The epidemiology of drugresistant malaria. Trans R Soc Trop Med Hyg 84: 177-180.
14. World Health Organization, 2012. Country antimalarial drug policies by region. Available at: http://www.who.int/malaria/am-drug-policies-by-region- afro/en/index.html. Accessed January 2013.
15. World Health Organization, 2012.WHO Policy Recommendation: Seasonal Malaria Chemoprevention (SMC) for Plasmodium falciparum malaria control in highly seasonal transmission areas of the Sahel sub-region in Africa. Available at: http://www .who.int/malaria/publications/atoz/smc-policy-recommendation-en- 032012.pdf. Accessed January 2013.
16. Frosch AEP, Venkatesan M, Laufer MK, 2011. Patterns of chloroquine use and resistance in sub-Saharan Africa: a systematic review of household survey data and molecular data. Malar J 10: 116.
17. O'Connell KA, Gatakaa H, Poyer S, Njogu J, Evance I, Munroe E, Solomon T, Goodman C, Hanson K, Zinsou C, Akulayi L, Raharinjatovo J, Arogundade E, Buyungo P, Mpasela F, Adjibabi CB, Agbango JA, Ramarosandratana BF, Coker B, Rubahika D, Hamainza B, Chapman S, Shewchuk T, Chavasse D, 2011. Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries. Malar J 10: 326.
18. USAID. Measure DHS Demographic Health Surveys. Available at: http://www.measuredhs.com/. Accessed January 2013.
19. Childinfo. Multiple Indicator Cluster Surveys. Available at: http://www.childinfo.org. Accessed January 2013.
20. Naidoo I, Roper C, 2010. Following the path of most resistance: dhpsK540E dispersal in African Plasmodium falciparum. Trends Parasitol 26: 447-456.
21. Naidoo I, Roper C, 2011. Drug resistance maps to guide intermittent preventive treatment of malaria in African infants. Parasitology 138: 1469-1479.
22. Flegg JA, Patil AP, Venkatesan M, Roper C, Naidoo I, Hay SI, Sibley CH, Guerin PJ, 2013. Spatiotemporal mathematical modelling of mutations of the dhps gene in African Plasmodium falciparum. Malar J 12: 249.
23. Mwai L, Ochong E, Abdirahman A, Kiara SM, Ward S, Kokwaro G, Sasi P, Marsh K, Borrmann S, Mackinnon M, Nzila A, 2009. Chloroquine resistance before and after its withdrawal in Kenya. Malar J 8: 106.
24. Malisa AL, Pearce RJ, Abdulla S,Mshinda H, Kachur PS, Bloland P, Roper C, 2010. Drug coverage in treatment of malaria and the consequences for resistance evolution-evidence from the use of sulphadoxine/pyrimethamine. Malar J 9: 190.
25. Kublin JG, Cortese JF, Njunju EM, Mukadam RAG, Wirima JJ, Kazembe PN, Djimdé AA, Kouriba B, Taylor TE, Plowe CV, 2003. Reemergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis 187: 1870-1875.
26. Mita T, Kaneko A, Lum JK, Bwijo B, Takechi M, Zungu IL, Tsukahara T, Tanabe K, Kobayakawa T, Björkman A, 2003. Recovery of chloroquine sensitivity and low prevalence of the Plasmodium falciparum chloroquine resistance transporter gene mutation K76T following the discontinuance of chloroquine use in Malawi. Am J Trop Med Hyg 68: 413-415.
27. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Coulibaly D, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV, 2001. A molecular marker for chloroquine-resistant falciparum malaria. N Engl J Med 344: 257-263.
28. Kazanjian P, Locke AB, Hossler PA, Lane BR, Bartlett MS, Smith JW, Cannon M, Meshnick SR, 1998. Pneumocystis carinii mutations associated with sulfa and sulfone prophylaxis failures in AIDS patients. AIDS 12: 873.
29. van Eijk AM, Hill J, Alegana VA, Kirui V, Gething PW, ter Kuile FO, Snow RW, 2011. Coverage of malaria protection in pregnant women in sub-Saharan Africa: A synthesis and analysis of national survey data. Lancet Infect Dis 11: 190-207.
30. The Global Fund to Fight AIDS TaM. Affordable Medicines Facility - Malaria. Available at: http://www.theglobalfund.org/en/amfm/. Accessed November 2012.
31. Shewchuk T, O'Connell KA, Goodman C, Hanson K, Chapman S, Chavasse D, 2011. The ACTwatch project: methods to describe anti-malarial markets in seven countries. Malar J 10: 325.